PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Daver, N. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Jabbour, E. [1 ]
Borthakur, G. [1 ]
Pierce, S. [1 ]
Vaughan, K. [1 ]
Vaughan, K. [1 ]
Ning, J. [2 ]
Gonzalez, G. [2 ]
Pemmarjau, N. [1 ]
Kadia, T. [1 ]
Konopleva, M. [1 ]
Andreeff, M. [1 ]
DiNardo, C. [1 ]
Cortes, J. [1 ]
Ward, R. [3 ]
Craig, A. [3 ]
Ravandi, F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Sunesis Inc, San Francisco, CA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S505
引用
收藏
页码：187 / 188
页数：2
相关论文
共 50 条
  • [1] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    BLOOD, 2014, 124 (21)
  • [2] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Daver, Naval
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Brandt, Mark
    Pierce, Sherry
    Vaughan, Kenneth
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Patel, Keyur
    Jorgensen, Jeffery
    Pemmaraju, Naveen
    Kadia, Tapan
    Konopleva, Marina
    Andreeff, Michael
    DiNardo, Courtney
    Cortes, Jorge
    Ward, Renee
    Craig, Adam
    Ravandi, Farhad
    HAEMATOLOGICA, 2017, 102 (10) : 1709 - 1717
  • [5] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Daver, N.
    Kantarjian, H.
    Ravandi, F.
    Estey, E.
    Wang, X.
    Garcia-Manero, G.
    Jabbour, E.
    Konopleva, M.
    O'Brien, S.
    Verstovsek, S.
    Kadia, T.
    Dinardo, C.
    Pierce, S.
    Huang, X.
    Pemmaraju, N.
    Diaz-Pines-Mateo, M.
    Cortes, J.
    Borthakur, G.
    LEUKEMIA, 2016, 30 (02) : 268 - 273
  • [6] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    N Daver
    H Kantarjian
    F Ravandi
    E Estey
    X Wang
    G Garcia-Manero
    E Jabbour
    M Konopleva
    S O'Brien
    S Verstovsek
    T Kadia
    C Dinardo
    S Pierce
    X Huang
    N Pemmaraju
    M Diaz-Pines-Mateo
    J Cortes
    G Borthakur
    Leukemia, 2016, 30 : 268 - 273
  • [7] A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul C.
    Scott, Bart L.
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, H. Joachim
    Walter, Roland B.
    Wang, Lixia
    Singer, Jack
    Estey, Elihu H.
    Pagel, John
    BLOOD, 2014, 124 (21)
  • [8] Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul
    Scott, Bart
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, Hans Joachim
    Walter, Roland
    Wang, Lixia
    Myint, Han
    Singer, Jack W.
    Estey, Elihu
    Pagel, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (02) : 238 - 245
  • [9] Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Chen, Y.
    Kantarjian, H.
    Garcia-Manero, G.
    Estrov, Z.
    Konopleva, M.
    Jabbour, E.
    Kadia, T. M.
    Williams, E.
    George, S.
    Borthakur, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
    Swaminathan, Mahesh
    Dinardo, Courtney Denton
    Maiti, Abhishek
    Pemmaraju, Naveen
    Ohanian, Maro
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Short, Nicholas James
    Wierda, William G.
    Jain, Nitin
    Kornblau, Steven Mitchell
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345